Valuation: Moderna, Inc.

Market Cap 5.79TCr 4.96TCr 4.64TCr 4.25TCr 7.98TCr 5,54400Cr 8.08TCr 55TCr 21TCr 2,78500Cr 22TCr 21TCr 9,21100Cr P/E 2026 *
-16.9x
P/E 2027 * -29.8x
Enterprise Value 5.43TCr 4.65TCr 4.35TCr 3.98TCr 7.48TCr 5,19500Cr 7.57TCr 51TCr 20TCr 2,60900Cr 20TCr 20TCr 8,63100Cr EV / Sales 2026 *
25.8x
EV / Sales 2027 * 22.7x
Free-Float
92.68%
Yield 2026 *
-
Yield 2027 * -
1 day-3.83%
1 week+129.20%
Current month+164.74%
1 month+154.52%
3 months+209.58%
6 months+188.59%
Current year+392.13%
1 week 62.13
Extreme 62.1293
176.66
1 month 52.66
Extreme 52.6601
176.66
Current year 29.81
Extreme 29.81
176.66
1 year 22.28
Extreme 22.28
176.66
3 years 22.28
Extreme 22.28
176.66
5 years 22.28
Extreme 22.28
464.85
10 years 11.54
Extreme 11.54
497.49
Manager TitleAgeSince
Chief Executive Officer 54 01/03/2011
Director of Finance/CFO 49 06/09/2022
President 50 01/11/2024
Director TitleAgeSince
Chairman 63 01/02/2012
Director/Board Member 54 01/03/2011
Director/Board Member 69 11/12/2019
Date Insider Type Main position Quantity % Market Cap.
06/08/26 Fiscal year

Chief Executive Officer

5,04,938 0.1273%
15/07/26 Fiscal year

Chairperson

1,60,008 0.0403%
08/07/26 Free

Director

14,766 0.0037%
Change 5-day change 1-year change 3-year change Capi.($)
-4.94%+129.20%+435.14%+25.70% 5.79TCr
-0.02%+3.80%+41.49%-0.81% 8.33TCr
+0.48%+25.64%-21.85%-35.91% 5.78TCr
-1.46%+0.19%-2.06%+32.21% 5.17TCr
-0.45%+2.51%+9.85%+170.99% 4.93TCr
-0.45%+3.31%+55.61%-18.13% 3.2TCr
-0.66%+6.37%+50.29%+97.70% 2.59TCr
-2.83%+4.35%-0.45%+187.16% 2.27TCr
-1.76%-1.27%+55.75%+107.91% 1.69TCr
-5.74%+1.91%-1.42%+796.55% 1.61TCr
Average -1.68%+18.61%+62.23%+136.34% 4.14TCr
Weighted average by Cap. -1.29%+24.08%+76.81%+73.20%

Financials

2026 *2027 *
Net sales 210.64Cr 180.43Cr 168.83Cr 154.54Cr 290.03Cr 20TCr 293.86Cr 1.99TCr 777.85Cr 10TCr 790.93Cr 773.72Cr 33TCr 245.73Cr 210.49Cr 196.95Cr 180.29Cr 338.34Cr 24TCr 342.81Cr 2.33TCr 907.42Cr 12TCr 922.68Cr 902.61Cr 39TCr
Net income -337.89Cr -289.44Cr -270.82Cr -247.91Cr -465.25Cr -32TCr -471.4Cr -3.2TCr -1.25TCr -16TCr -1.27TCr -1.24TCr -54TCr -189.53Cr -162.35Cr -151.91Cr -139.06Cr -260.97Cr -18TCr -264.42Cr -1.79TCr -699.9Cr -9.11TCr -711.67Cr -696.19Cr -30TCr
Net Debt -364.91Cr -312.58Cr -292.47Cr -267.72Cr -502.44Cr -35TCr -509.08Cr -3.46TCr -1.35TCr -18TCr -1.37TCr -1.34TCr -58TCr -219.36Cr -187.91Cr -175.82Cr -160.94Cr -302.04Cr -21TCr -306.03Cr -2.08TCr -810.06Cr -11TCr -823.69Cr -805.77Cr -35TCr
Logo Moderna, Inc.
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).
Employees
4,700
Date Price Change Volume
22/26/22 $145.13 +8.86% 8,73,16,065
20/26/20 $133.32 -23.55% 9,94,99,941
19/26/19 $174.38 +176.97% 19,92,52,328
18/26/18 $62.96 -2.33% 43,04,996
17/26/17 $64.46 +1.80% 39,79,550
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
23
Last Close Price
145.13USD
Average target price
91.39USD
Spread / Average Target
-37.03%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MRNA Stock